A new Gavi market shaping roadmap for HPV vaccines showcases how partners, manufacturers and countries must work together to secure a sustainable supply over the next decade.
Aurélia Nguyen, Chief Programme Officer at Gavi:"Lower-income countries have missed out on HPV vaccines for far too long. To ensure we reach our goal of protecting 86 million girls by 2025, it's vital that our current supply of doses is managed carefully, and we have donor and manufacturer support to go further and protect more girls."
For over a decade, Gavi has been working to address historical supply challenges while supporting countries to protect 16.3 million adolescent girls with the HPV vaccine. However, these challenges, combined with barriers to accessing the HPV vaccine and the COVID-19 pandemic, led to a concerning drop in coverage of the HPV vaccine across lower-income countries.
To achieve its vision of a healthy vaccine market, Gavi has highlighted four key market objectives, each of which is underpinned by target outcomes: supply meets demand to support HPV vaccine programme implementation; predictability of medium- to long-term demand is enhanced to facilitate secure supply of affordable vaccines; diversity of products suitable for different country contexts is achieved with healthy competition between suppliers; and future innovations for potentially new HPV...